The Monday Brief — Week of Jul 14, 2026

Steel Partners, already a major InMode shareholder, launched an unsolicited $16.75-per-share cash offer this week, challenging a CEO-led buyout proposal. InMode stock surged on the news. The company is defending its position while the board weighs options—and court filings suggest the process could face delays. What matters to you: InMode's Morpheus8 and BodyTite platforms dominate your RF and body-contouring revenue. A change in ownership could shift pricing, rebate structures, and support priorities. Watch the board's next move and any revised offers.

Medicare will negotiate Botox pricing this year alongside 14 other drugs—a first for the category. Both AbbVie (Allergan Aesthetics) and Evolus filed material SEC events signaling aggressive counter-moves: Allē loyalty rebates from Allergan and Evolus Rewards from Evolus, plus aggressive medspa marketing. Translation: price wars are starting. Expect margin pressure on every unit sold. Lock in your Q3 contracts now and model scenarios where per-unit reimbursement drops 5–10%.

Evolus secured a 15-year exclusive U.S. license for Profhilo (skin-quality injectable) from IBSA—no upfront fees, expanding its injectables portfolio beyond neuromodulators. Meanwhile, Cynosure Lutronic rolled out XERF, a next-generation monopolar RF platform, across Europe and is accelerating adoption in North America. Both moves target non-invasive skin tightening and quality—high-margin services. If you don't yet offer RF body tightening or skin-quality injectables, competitive pressure is mounting. Evaluate your platform roadmap.

SkinStylus earned new FDA clearance for periorbital wrinkles across all skin types. Candela's Nordlys fractional laser published a peer-reviewed study in Nature Scientific Reports showing epigenetic reversal of aging—strong marketing ammunition. The fractional RF microneedle market is projected at $2.3 billion. These clearances and data points reinforce that non-invasive body and face treatments remain the growth engine. Ensure your clinical team can articulate the science to patients and payers.

Millennials are now nearly matching Gen X in neuromodulator use, and seven FDA-approved neuromodulators are now in play (with more pending). Daewoong's Nabota crossed 1 trillion won in cumulative sales and is accelerating its global push. Galderma's RelabotulinumtoxinA regulatory submission is progressing in the U.S. The category is no longer Botox-only; patient choice and brand loyalty are fragmenting. Stock multiple brands, train staff on differentiation, and don't assume Botox loyalty.

L'Oréal raised its stake in Galderma to 20%, signaling confidence in the aesthetics-injectables market. Hugel, the Korean manufacturer behind Nabota, is scaling production—turning a thumb-sized tube into 25,000 toxin vials. These moves reflect consolidation and manufacturing capacity expansion at the top of the supply chain. Expect tighter supply chains, potential price volatility, and faster product launches. Diversify your supplier relationships and negotiate multi-year contracts where possible.